41.00 -0.21 (-0.51%)
After hours: 5:01PM EDT
|Bid||40.90 x 900|
|Ask||41.88 x 1000|
|Day's Range||41.13 - 41.40|
|52 Week Range||36.41 - 42.36|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||41.54|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.39 (5.79%)|
|1y Target Est||44.33|
United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare. The world's largest package delivery firm is preparing to test a U.S. service that dispatches nurses to vaccinate adults in their homes, Reuters has learned, as the company and its healthcare clients work to fend off cost pressures and competitive threats from Amazon.com. UPS did not disclose which vaccines it would be using in the project, but drug and vaccine maker Merck & Co told Reuters it is looking at partnering with the company for the initiative.
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have set GlaxoSmithKline’s (GSK) 12-month consensus target price at $44.33, 9.48% higher than the
A new GlaxoSmithKline subsidiary is developing another cancer-fighting drug that it believes could go toe-to-toe with the current market leader, Merck’s blockbuster drug Keytruda.
GSK said it would apply for marketing approval for dostarlimab in endometrial cancer at the end of 2019. GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion (3.8 billion pounds) in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
[Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market has made a huge improvement at the start of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to invest in now,disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to invest in are those that dropped by double-digit percentages during the current rally.Why is that?Markets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% With all of that in mind, here are five undervalued stocks to invest in that aren't as scary as they seem. Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Sony is clearly not a broken company, so the stock's drop from $50 on Feb. 1 to $46 appears overdone. Trading less than 10% above its 52-week low and about 25% below its 52-week high, Sony stock clearly deserves its spot among the best undervalued stocks to consider now. Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is an undervalued play worth considering. Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) fell over 10% in late January and early February for two reasons. First, its fourth-quarter earnings report did not please investors. Operating income sank 11.8% year-over-year, and revenue fell 5.8% YoY to $4.08 billion.On Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for investors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 7.7, the price-earnings-to-growth ratio is 0.39. As such, this general pessimism has created an appealing entry point to INVA stock. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to invest in now. Vodafone (VOD)Telecom stocks are out of favor. For example, just look at AT&T (NYSE:T), which is down over 20% from its 52-week high. But Vodafone (NASDAQ: VOD) is down the most among the major names in the sector, falling over 40% from its 52-week high.Third-quarter results for VOD, which ended on Dec. 31, missed analysts' consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield in excess of 6%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 5 Undervalued Stocks to Invest In appeared first on InvestorPlace.
The United Kingdom has one of the strongest economies in the world thanks to the strength of its services, manufacturing construction and tourism sectors.
A new ranking of life science hubs has the Triangle in the top five in the nation – due to its exploding growth and deep talent pool.
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings conference call, Pfizer (PFE) forecasted that its fiscal 2019 revenues would fall in the range of $52
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Congressional hearings underway are creating plenty of unnecessary uncertainties for life sciences stocks in the generic drug space. Government oversight over how drugs are priced could put even more pressure on generics and hurt life sciences stocks.With no exclusivity and more reasons for firms to battle each other on the lowest price, investors are selling companies facing generic drug competition now and asking questions later. That reaction is irrational: governments may end up doing nothing to change the drug sales model that is vital to life sciences stocks. * 7 March Madness Stocks to Consider for the Big Dance Here are the three life sciences stocks whose shares took a tumble very recently.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Life Sciences Stocks: Teva Pharmaceuticals (TEVA)Teva Pharmaceuticals (NYSE:TEVA) reported respectable 2018 revenue of $18.9 billion and free cash flow of $3.7 billion. Its acquisition of Actavis Generics significantly strained its balance sheet but the company still managed to reduce net debt by 14% to $27.1 billion. Teva launched Ajovy, an injectable prescription drug that is used to prevent migraine headaches in adults. Austedo, which treats tardive dyskinesia and Huntington's disease, is growing rapidly.Copaxone maintained its market share in the U.S. with $1.697 billion in net sales in 2018. The prescription or TRx share was around 21.8%. In the 40mg space, Copaxone took 74.7% share of the 40mg glatiramer acetate market (as of December 2018).Markets are not so optimistic about the generic competition for Copaxone. It reacted by selling the stock when it reached $20, pushing it down to around $17 a share after the Q4 earnings report.Teva is prepared for the pricing pressure it faces for Copaxone, where generic competition will hurt most in the U.S. Outside of this region, the situation is more stable. Astute investors will watch the sales growth for Audtedo and Ajovy, whose revenue needs to offset the sales declines in Copaxone. Mylan N.V. (MYL)Mylan N.V. (NASDAQ:MYL) is Teva's competitor because it recently launched a generic to Copaxone. Unfortunately, the downward trend in the stock in the last year capitulated with the stock falling even further, from around $32 to $26, after the fourth-quarter earnings report. Mylan reported the uptake of its generic Copaxone was slower than management expected. Cutting prices by over 60% did not help sales.Slow uptake for its generic Copaxone and delayed approval of its generic Advair hurt fourth-quarter results and the 2019 outlook. Despite those issues, Mylan reported a healthy $11.4 billion in total revenue in 2018 and $2.7 billion in adjusted free cash flow. It paid back more than $630 million in debt.For the Morgantown plant issue, in which it received a warning letter regarding previously disclosed observations. Mylan took a $258 million restructuring and remediation expense. Investors might assume the problems at this location will get resolved, but for now, markets may continue to punish the stock for its less than perfect operating record. * 9 Best Stocks to Buy on U.S.-China Trade Optimism At a free cash flow forecast of $1.9 billion-$2.1 billion in 2019, management could do two things to enhance shareholder buyback. First, buying back stock would help EPS for the year. Second, initiating a dividend would reward investors who are patiently holding the stock. GlaxoSmithKline (GSK)Even though GlaxoSmithKline's (NYSE:GSK) Advair faces competition from Mylan's generic to the drug, the stock is performing relatively well. Not only are valuations still reasonable at a 20.8 times P/E and 13.6 times forward P/E according to Morningstar, but GlaxoSmithKline's stock pays a dividend yielding 5.1% over the past year.On Feb. 12, Mylan launched Wixela Inhub, at a list price that is 70% below that of Advair Diskus and 67% below GSK's authorized generic version. Even before the launch, U.S. Advair sales fell 30%. With the competition modeled in its outlook, GlaxoSmithKline still expects a significant decline in Advair this year. So, why are markets not worried about this news? Markets rewarded the stock after the company posted fourth-quarter results.GSK posted revenue growth of 7.3%, to £8.2B billion. 2019 will be another strong year, with the HIV business being led with two drug regimens. This will follow the 2018's 16% growth of dolutegravir. Looking ahead, approval of its dolutegravir and lamivudine combination in its second quarter will help GSK maintain its 27% market share in the U.S.GSK's balance sheet is solid. Free cash flow grew by £2.2 billion to £5.7 billion last year. This will ensure the company continues to pay a dividend at the same amount as last year. Its debt increased, driven primarily by its buy-in of Novartis' consumer stake. It's a standout among life sciences stocks.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio Compare Brokers The post 3 Life Sciences Stocks to Invest In appeared first on InvestorPlace.
Amarin Stock: The Outlook after the Q4 2018 ResultsShare price movements On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of